Cliff Asness's CRSP Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 20,746 shares of CRISPR Therapeutics AG (CRSP) worth $1.09 M, representing 0.00% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 10 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in CRSP, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 25,306 shares. Largest reduction occurred in Q3 2022, reducing 8,505 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's CRISPR Therapeutics (CRSP) Holding Value Over Time
Track share changes against reported price movement
Quarterly CRISPR Therapeutics (CRSP) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -7,626 | Reduce 26.88% | 20,746 | $52.44 |
| Q3 2025 | +6,758 | Add 31.27% | 28,372 | $64.81 |
| Q2 2025 | -3,692 | Reduce 14.59% | 21,614 | $48.64 |
| Q1 2025 | +25,306 | New Buy | 25,306 | $34.03 |
| Q3 2022 | -8,505 | Sold Out | 0 | $0.00 |
| Q2 2022 | -578 | Reduce 6.36% | 8,505 | $60.79 |
| Q1 2022 | +2,310 | Add 34.11% | 9,083 | $62.75 |
| Q4 2021 | +2,911 | Add 75.38% | 6,773 | $75.74 |
| Q3 2021 | +1,661 | Add 75.47% | 3,862 | $111.86 |
| Q2 2021 | +2,201 | New Buy | 2,201 | $161.74 |
Cliff Asness's CRISPR Therapeutics Investment FAQs
Cliff Asness first purchased CRISPR Therapeutics AG (CRSP) in Q2 2021, acquiring 2,201 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held CRISPR Therapeutics AG (CRSP) for 10 quarters since Q2 2021.
Cliff Asness's largest addition to CRISPR Therapeutics AG (CRSP) was in Q1 2025, adding 25,306 shares worth $861,163.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 20,746 shares of CRISPR Therapeutics AG (CRSP), valued at approximately $1.09 M.
As of the Q4 2025 filing, CRISPR Therapeutics AG (CRSP) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in CRISPR Therapeutics AG (CRSP) was 28,372 shares, as reported at the end of Q3 2025.